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Introduction
Currently, ovarian cancer is the sixth most com-
mon cancer worldwide among women in developed 
countries and the most lethal of all gynaecologic ma-
lignancies [1]. Unfortunately, most women have ad-
vanced-stage disease at the time of diagnosis [2]. Com-
plete cytoreductive surgery is necessary for significant 
survival benefit [3]. Recent data suggest that even ter-
tiary cytoreductive (TCR) surgery in recurrent epitheli-
al ovarian cancer (EOC) to achieve no residual disease 
postoperatively is associated with significantly longer 
overall survival in selected patients [4]. However, data 
regarding metastases to the urinary tract system are 
rather scarce. Metastatic involvement of the urinary 
tract in patients with advanced ovarian carcinoma were 
evaluated during autopsy. The distribution of metasta-
tic sites was as follows: kidney 3.5%, urinary bladder 
22.4% and ureter 11.8% [5].
Case report
We present a case of a 61-year-old woman with re-
current ovarian cancer infiltrating the right ureter. It is 
10 years since her primary operation with a diagnosis 
of FIGO (International Federation of Gynecology and 
Obstetrics) stage IIB EOC (epithelial ovarian cancer- 
cystadenocarcinoma solidum, partim papillare serosum 
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ovariorum). After the primary operation 6 courses of 
adjuvant chemotherapy based on paclitaxel and the 
platinum analogue carboplatin were introduced.
Routine preoperative examination was performed 
in the study patient. Computed tomography (CT) scans 
of the chest, abdomen, and pelvis and tumour markers 
(CEA, CA19-9, and CA125) were obtained. Definitive pri-
mary cytoreductive surgery was carried out to achieve 
complete cytoreduction using the following procedures: 
laparotomy, abdominal wall resection, abdominal and 
pelvic lymphadenectomy, appendectomy, and bilateral 
adnexectomy with hysterectomy, cytoreductive surgery 
and biopsy of peritoneal implants, enterolysis, uretero-
lysis, and omentectomy. The peritonectomy procedures 
also include diaphragmatic, parietal, and pelvic peri-
tonectomy, but it was not necessary in this case. Resec-
tion of hollow viscus and/or organs is also performed if 
they cannot be cleared of disease or were affected by 
the primary cancer, but these procedures were not nec-
essary in this case and every effort was made to avoid 
extensive small bowel resection and/or stoma forma-
tion to preserve quality of life. Complete cytoreduction 
was defined as nodules less than 2.5 mm in size (CC = 1) 
or the absence of visible tumour nodules (CC = 0) and 
complete cytoreduction was achieved during primary 
surgery. However, after 8 years recurrence of the ovar-
ian cancer was diagnosed and during the secondary 
surgery two tumours infiltrating the right iliac vessels 
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nary bladder, it was temporarily filled with 0.9% sterile 
saline solution. Following the ureter, a change outside 
the bladder location was clearly identified. This tumour 
did not infiltrate the bladder wall and was easily bleed-
ing when touched. Cutting 2 cm above the ureteral le-
sion and the tumour removal sharply in the range of 
macroscopically unchanged tissues were performed. 
The tumour was removed by stump and blind dissection 
with 2 cm of infiltrated ureter. Then the specimen was 
put into an endobag and removed. Then, the ureteral 
stump was transplanted into the bladder using a psoas 
high manoeuvre without producing an outflow mecha-
nism. The anterior and lateral wall of the bladder was 
released so that it reached the ilium-lumbar muscle on 
the right side. With two sutures, the bladder was pulled 
up and attached. Then, in the top a longitudinal bladder 
incision and adequate ureteral spatulation were per-
formed. Single monofilament sutures were used end-
to-end to perform anastomosis. A new 2JJ catheter was 
introduced into the ureter. The bladder was closed by 
running suture arch and water tightness was checked 
at 100 ml. Haemostasis control was performed. A drain 
was left in the area of the anastomosis. The bladder 
catheter was left for 3 weeks. On the 4th day after the 
surgery, the drain, which had received a trace amount 
of serous content, was removed. After 6 weeks, the 2JJ 
catheter was removed. The post-operative CT scan re-
vealed proper functioning of the right kidney and the 
free passage of contrasted urine into the bladder.
After the operation histopathology of the tumour 
was performed. The specimen consisted of fibromuscu-
lar tissue with infiltrate of moderately to poorly differ-
entiated adenocarcinoma. The tumour formed papillary 
and tubular structures lined by cylindrical cells with 
a high nuclear-cytoplasmic ratio and nuclear atypia. Fo-
cally the epithelium was more multi-layered with slight 
similarity to urothelium. There were small areas of ne-
and pelvis wall (diameter 3 cm), with pressure to the 
right ureter, and peritoneum of the caecum (diameter 
2 cm). According to intraoperative inspection resection 
of the greater tumour was incomplete but the caecum 
metastasis was completely removed. Histological ex-
amination of the specimens was as follows: adenocar-
cinoma papillare serosum ex ovario CK7 (+), CK20 (–), 
WT-1 (+). According to urologist consultation a double-J 
(2JJ) catheter was placed after surgery to protect the 
function of the right kidney. However, the CT scan af-
ter surgery was normal based on RECIST criteria and 
the patient received 6 courses of adjuvant chemother-
apy based on paclitaxel and carboplatin. Unfortunately, 
2 years later the patient was admitted to perform 
surgery in order to remove the ovarian tumour recur-
rence located in the small pelvis. This tumour infiltrat-
ed the dilated right ureter above the bladder, causing its 
complete obstruction and right-sided hydronephrosis 
(Figs.  1 and 2). For this reason, a 2JJ catheter (pigtail) 
was placed before surgery to protect the function of 
the right kidney. In the CT examination with contrast, 
the cortical layer of this kidney was visible in the pa-
renchymal phase without impaired urine transport to 
the bladder. The operation was performed laparoscop-
ically using the Olympus Viscera Visual Track with 3D 
visualization. After the catheterization of the urinary 
bladder insufflation was created near the navel access 
to the peritoneal cavity by minilaparotomy through the 
10 mm optical port. The patient was then placed in 
a Trendelenburg position with an angle of 22 degrees. 
The 4 ports (3-5 mm and 1-10 mm) were placed in a 
typical way for pelvic urological operations (Fig. 3). The 
ureter was initially identified at the height of the iliac 
vessels after peritoneal incision. Afterwards, the retro-
peritoneal space on the right side was exposed, cutting 
the peritoneum along the iliac vessels and then over 
the pubic symphysis. For better identification of the uri-
Fig. 1. Tumour infiltrating right ureter, 
PET-CT scan of the pelvis
Fig. 2. Tumour infiltrating right ureter, 
PET-CT scan of the pelvis
Fig. 3. The ports' location for pelvic uro-
logical operations
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crosis and significant mitotic activity. On immunohisto-
chemistry, the tumour cells expressed WT1 and oestro-
gen receptor, but were negative for GATA3. Basing on 
these finding and on the case history, the diagnosis of 
relapsing high grade serous ovarian carcinoma could be 
established (Figs. 4-6).
Finally, according to the BRCA-1 + status in the spec-
imen after the final operation the patient was assigned 
to receive maintenance therapy with olaparib. In addi-
tion, BRCA-1 mutation was negative in the blood of the 
study patient. CT scans did not reveal any abnormali-
ties. At the moment, it is more than one year after the 
patient’s TCR surgery and she feels fine.
Discussion
Recently, complete en bloc tumour resection with 
the right external and internal iliac artery and vein, right 
ureter, vagina, and rectum adhering to the tumour has 
been described. The authors concluded that exfoliation 
from the sacral plexus and total resection with external 
and internal iliac vessels enables complete resection of 
the tumour fixed to the pelvic sidewall [6]. Surgical pro-
cedures involving the urinary tract may be necessary to 
achieve optimal surgery in patients with ovarian peri-
toneal carcinomatosis with reasonable rates of post-
operative morbidity [4, 6, 7]. Proper patient selection 
is the most important to have a chance of complete 
cytoreduction [4, 6, 7]. In the study case, the quality 
of life has been taken into account during the entire 
therapy. Modern management of recurrent ovarian 
cancer compromises various combinations of system-
ic chemotherapy with or without targeted agents since 
most patients with advanced-stage epithelial ovari-
an cancer will experience a relapse of disease despite 
a complete response after surgery and platinum-based 
chemotherapy [3]. Therefore, recent data suggest that 
olaparib (PARP inhibitor) provides a significant progres-
sion-free survival improvement with no detrimental ef-
fect on quality of life in patients with platinum-sensitive 
relapsed ovarian cancer and a BRCA1/2 mutation [8]. 
Another drug, prexasertib, a cell cycle checkpoint kinase 
1 and 2 inhibitor, also showed clinical activity in BRCA 
wild-type high-grade serous ovarian carcinoma [9]. 
Olaparib was used as a maintenance therapy in the study 
patients according to the national program in Poland. 
WT1 is a useful immunohistochemical marker in diag-
nosis of high-grade serous carcinoma. The sensitivity 
and specificity for diagnosis of high-grade serous carci-
noma were found to be 96 and 100%, respectively [10]. 
Therefore, optimal surgery, chemotherapy and histo-
pathology are the key steps leading to success in the 
therapy of relapsed ovarian cancer.
Despite the effect of various tumour biological fac-
tors such as grading and histological subtype, the sur-
gical outcome is still the most important prognostic 
factor for both progression-free and overall survival [11]. 
However, the management of cancer has remained 
a subject of an international discussion. Therefore, only 
Fig. 4. Papillary and tubular architecture of the tumour. Hae-
matoxylin and eosin, 100×
Fig. 6. Strong nuclear reaction for WT1. Immunohistochemistry, 
200×
Fig. 5. Prominent cellular atypia with high nuclear-cytoplasmic 
ratio, pleomorphic and mitotic figures. Haematoxylin and eosin, 
400×
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a few prospective studies have focused on the effect of 
surgery in relapsed ovarian cancer. The impact of TCR 
on survival in EOC and predictors of complete cytore-
duction were analysed in patients with a ≥ 6-month 
treatment-free interval (TFI), recently. Almost 70% of 
the patients achieved complete cytoreduction with se-
vere post-operative complications in less than 10% and 
no cases of mortality within 60 days from surgery [4]. 
It has been established that women who underwent pri-
mary complete cytoreduction are in good performance 
status, and those who have only a minimal ascites vol-
ume (less than 500 ml) in the recurrent situation have 
76% likelihood of undergoing complete resection and 
survival prolongation. The benefit seems to be greater 
in patients with TFI > 12 months showing a single-site 
recurrence disease, in which complete cytoreduction 
is achievable [12]. Therefore, preoperative assessment 
of patients and weighing the potential survival benefit 
against potential surgical risks are very important for 
patient selection [13]. In addition, postoperative tu-
mour residual disease remains the strongest predictor 
of survival in TCR [14].
Conclusions
In conclusion, the challenge for the future is multi-
disciplinary cooperation between an oncological gynae-
cologist, urologist and clinical oncologist in recurrent 
ovarian cancer management involving metastases to 
the urinary system.
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